Articles tagged with Tumor Cells
Researchers found that cells with damaged DNA trigger a mechanism to signal natural killer cells, which attack and destroy cancerous cells. The immune system's ability to identify cancer cells is crucial in preventing tumor growth.
Increased expression of claudin-1 has been found in human primary colon carcinomas and metastases. Claudin-1's mislocalization is associated with higher levels of expression and increased metastatic behavior in colon cancer cells.
Researchers have identified a novel type of lung cell that can divide into fresh copies and specialized types, suggesting these cells may contribute to the development of most common lung cancers. The discovery could lead to earlier diagnosis and potentially more effective treatments for lung cancer.
Researchers found that a vaccine targeting TRP-2 improves chemotherapy sensitivity in brain tumors. The study showed significant improvements in patient survival and tumor response rates compared to conventional treatments.
Researchers discovered that EGFR interacts with STAT3 in the cell nucleus, leading to increased expression of inducible nitric oxide synthase (iNOS) and a new transcriptional mechanism in human cancers. This interaction provides a potential target for anticancer therapies against EGFR, STAT3, and iNOS/NO.
Researchers study natural products that may prevent certain cancers. Propolis and turmeric, rich in plant polyphenolic compounds, exhibit potent antitumor activities, protecting mice against radiation-induced inflammation and rats against chemotherapy-induced heart muscle damage.
A study published in the Journal of Clinical Investigation has identified a new protein called SPARC that plays a crucial role in tumor therapy resistance. The researchers found that restoring SPARC expression in resistant cells improved their sensitivity to chemotherapy, suggesting potential therapeutic applications.
A Medical College of Georgia researcher has developed a mouse model to study the immune system's initial response to cancer. The goal is to understand how the body decides which cancer cells to attack and which to ignore, in hopes of developing new treatments that utilize the body's natural defenses.
A University of Central Florida researcher has discovered a protein called MKRN1 that promotes the destruction of telomerase, an enzyme that enables rapid cell division. The study suggests that MKRN1 could be a critical component in preventing cancer cells from replicating uncontrollably.
Researchers have developed a novel delivery system that uses siRNA to silence the growth-promoting gene EWS-FLI1 in tumor cells, effectively inhibiting cell replication by 80%. The nanoparticles are designed to target specific tumor sites and avoid degradation, making them a promising treatment option for Ewing's sarcoma.
Researchers have discovered a new treatment that uses a chemical to prevent PARP repair, making recombination essential for cancer cell growth. This approach shows promise as a potential breakthrough for women with hereditary breast cancer.
Researchers at The Wistar Institute found that an initiating genetic error can lead to relentless cell division, causing DNA replication stress and breaks. This stress creates conditions for tumor progression and the accumulation of mutant genes, ultimately leading to cancer.
Researchers have identified a previously unknown protein called Fra-1 that controls cancer cells' malignant characteristics and spread to healthy tissue. The discovery, made in glioblastoma brain tumors, suggests new treatment possibilities for multiple cancers.
A new cancer test uses the physical strength of each cell to diagnose and stage cancer, reducing the need for biopsies and potentially saving lives. The 'optical stretcher' can detect cancer in as few as 50 cells, allowing for early diagnosis and treatment.
USC researchers found that the BRCA1 gene disrupts interactions between different cell types, leading to ovarian cancer. The gene's indirect action may lead to new treatment options by targeting a biochemical mediator.
Researchers discover ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, arrests cell division in human cancer cells and inhibits a variety of tumors. Clinical studies are currently underway to determine the best way to utilize this potent anticancer agent.
Researchers discovered a compound called STA-21 that blocks a key protein, Stat3, in breast cancer cells. This inhibition leads to the death of cancer cells and may increase effectiveness of chemotherapy while reducing treatment toxicity.
Researchers discover viral DNA sequence in MMTV Env protein that transforms mouse breast cells. The study suggests a potential new mechanism for virus-induced breast cell transformation.
Researchers successfully redirected human immune cells to target and kill cancer cells by introducing a specific gene that allows for high-affinity recognition of tumor-associated p53. This breakthrough approach holds promise for a novel, broad-spectrum immunotherapy for malignant diseases.
Research reveals that cancer cells can become resistant to treatment by acquiring P-glycoprotein from neighboring cells, rendering chemotherapy ineffective. This phenomenon has significant implications for tumor behavior and genomic analysis, highlighting the potential benefits of studying protein transfer between cells in tumors.
Researchers aim to understand the growth and spread of breast cancer by targeting tumor stem cells, which are hypothesized to perpetuate cancer growth. The project may lead to a critical adjunct therapy targeting these cells.
Researchers at University of Pittsburgh Medical Center found that overexpression of protein NuMA can cause changes in a cell associated with tumor formation. By studying the mechanism by which this occurs, the team identified a possible treatment target for some types of cancer.
Scientists have discovered a new gene, Bnip3L, that helps p53 eliminate cancer cells under low-oxygen conditions. Silencing this gene allows tumors to grow more aggressively in hypoxic environments.
Researchers at Cincinnati University and the University of Munich have identified a novel oncogene in papillary thyroid cancer cases among Chernobyl residents. This oncogene resulted from fusion of part of the AKAP9 gene with one end of the BRAF gene, leading to uncontrolled cell division and transformation into malignant tumor cells.
Researchers have identified a subset of tumor cells that resist inhibition of the Hedgehog signaling pathway, leading to cancer recurrence. However, targeting these residual cell populations could lead to effective treatment of basal cell carcinoma.
A recent study suggests that Akt3 protein is key to melanoma's resistance to chemotherapy, promoting tumor cell survival and development in 43-60% of non-inherited melanomas. Lowering Akt3 activity can reduce tumor-creating potential and make cancer cells more susceptible to signals inducing apoptosis.
Researchers have discovered a new gene, 15-PGDH, that acts as an antagonist to control the enzyme COX-2, a major early event in human colon tumors. The study found that 15-PGDH is directly controlled and activated by TGF-beta, and its presence can suppress COX-2 activity, potentially leading to tumor development without it.
Researchers at Scripps Research Institute use a class of compounds known as Src kinase inhibitors to stabilize blood vessels and block tumor cell metastasis. By increasing the protective barrier strength of host blood vessels, the approach prevents cancer cells from exiting the bloodstream, making them vulnerable to immune system attack.
Researchers have developed core/shell nanogels that can target cancer cells using folic acid, a nutrient that cancer cells absorb more than healthy cells. The nanoparticles can be heated to kill cancer cells, but applying targeted heat sources like ultrasound can spare healthy cells.
A study published in Cancer Cell found that zebularine slows cancer-cell growth by up to 68%, but only 21% in normal cells. The drug works by demethylating specific genes, offering a promising new approach to cancer treatment with fewer side effects.
Researchers developed a novel treatment combining chemotherapy, radiation therapy, and immunotherapy to target genetic mechanisms protecting metastatic tumor cells. The treatment successfully induced apoptosis in tumor cells by blocking oncogene expression and DNA synthesis.
Researchers have discovered a potential immunotherapy strategy for cancer treatment by reactivating specific memory T cell subsets from cancer patients. These activated cells effectively recognize and reject xenotransplanted autologous tumors, reducing tumor size in mice.
A study by Dana-Farber Cancer Institute researchers found that 36 out of 181 patients with Waldenstrom's macroglobulinemia had at least one first-degree relative with the disease. The study also found no discernible differences in age of onset, blood counts, or genetic analysis between family and non-family forms of the disease.
Researchers at UNC have identified a crucial role for a segment of Focal Adhesion Kinase (FAK) in activating the enzyme, which promotes cancer cell growth and metastasis. By making subtle changes to this region, they created a mutant protein that blocks FAK activity, suggesting potential therapeutic applications.
A new RNAi delivery system has been developed to target brain cancer cells, using antibodies to cross the blood-brain barrier. The treatment has shown promising results in mice with brain tumors, increasing survival time by almost twice as much as a control group.
Researchers have discovered a new way in which mutated Ras proteins contribute to cancer progression. They found that Ras interacts with an enzyme essential for the synthesis of GPI-anchored proteins, regulating their production on cell surfaces.
Researchers found that NKT cells are attracted to tumors producing the chemokine CCL2, leading to better patient outcomes. Neuroblastomas with abnormally high levels of the cancer-causing gene MYCN contained fewer NKT cells and produced less CCL2.
Researchers discovered that Nembutal suppresses colon cancer metastasis and improves post-radiation brain function. Additionally, erythropoietin was found to protect cognitive function after whole brain irradiation, while a new vitamin B12 molecule targets tumor cells.
Researchers discover IGF-1R inhibition significantly impacts tumor cell growth and sensitivity to chemotherapy, highlighting its potential as an anticancer therapeutic. Two selective inhibitors of IGF-1R are identified with potent antitumor activity against multiple myeloma and other hematological malignancies.
Researchers have discovered that protein cdk6 inhibits breast cancer cell growth, suggesting a promising avenue for diagnosis and treatment. Cdk6 levels were found to be significantly lower in breast cancer cells compared to normal cells, with increased expression of cdk6 linked to suppressed cell growth.
Researchers from Massachusetts General Hospital found that cancer cells can compress both blood and lymphatic vessels within tumors. This compression limits the delivery of anticancer drugs to tumor cells. New strategies for improving cancer treatment may be developed by normalizing distorted blood supply within tumors.
A study published in Nature Biotechnology found that the Sindbis virus is effective at killing tumors in mice, with varying time and injection schedules required. The virus targets tumor cells by binding to a specific receptor, making it a potential tracking device for cancer.
Researchers found that colon cancer cells can revert to non-metastatic behavior when surrounded by other cells, reversing the invasive process. By targeting a specific gene called Slug, scientists hope to develop a drug to block metastasis in patients.
Scientists have developed a method that uses allicin, found in garlic, to selectively kill cancer cells in mice. The method involves injecting an antibody and enzyme combination that targets specific receptors on cancer cells, triggering the production of lethal allicin molecules that destroy tumors while leaving healthy cells intact.
New class of drugs targets specific molecules within brain cancer cells, slowing growth and reducing side effects. Three drugs - ZD6474, SB431542, and AEE788 - demonstrate significant promise in treating glioblastoma and other types of brain tumors.
Researchers found that a specific protein expressed by the Epstein-Barr virus (EBV) is crucial for tumor cell proliferation and survival in Burkitt's lymphoma. Developing small molecules that target this protein could lead to effective therapies with minimal side effects, offering hope for patients with EBV-associated tumors.
Researchers have discovered a novel molecular mechanism that explains why certain Hsp90 inhibitors are effective against tumor cells while being non-toxic to normal tissues. This breakthrough has significant implications for the development of targeted cancer therapies and may lead to new treatments for various types of cancer.
Researchers have discovered a potential new treatment for certain types of cancer by inhibiting sphingosine kinase. The study found that targeting this enzyme can reduce tumor growth and induce apoptosis in cancer cells, offering hope for new targeted therapies.
Research suggests that cutting off blood vessels to starve tumors of oxygen may not always be effective, as it can also make them harder to treat. Instead, feeding the tumor with oxygen may be a more viable option to kill cancer cells.
Researchers discovered that aggressive cancer cells form vascular-like networks, allowing for blood flow and potential nutritional exchange. This 'chameleon-like' ability raises clinical challenges in detecting aggressive tumor cells but offers new insights into targeting them more effectively.
The UGA research team has identified a molecular key to cell division, which could lead to new targets for cancer therapeutics. The study found that cyclin-dependent kinases drive the mitosis process and that molecules called oncogenes and tumor suppressor genes are controlled by novel mechanisms.
Researchers found that Cripto overexpression inhibits Activin signaling, leading to increased tumor cell growth. Antibody blockade of Cripto suppresses tumor cell growth in xenograft models, suggesting a central role for Cripto in tumorigenesis.
Researchers at Ohio State University found that endostatin can stop Kaposi's sarcoma cells from growing new blood vessels and migrating through the body. The study suggests a controlled release of endostatin could be an effective treatment option for patients with KS.
Studies found that increasing TBP levels can contribute to oncogenesis, while p53 acts as a tumor suppressor by reducing TBP's effective concentration. These findings have implications for the development of new cancer treatments and therapies.
A new study connects a powerful cancer-causing protein to a gene associated with Werner syndrome, a disease causing premature aging. Researchers suggest developing drugs that interfere with the WRN gene's anti-aging properties to block Myc's tumor-promoting activity.
Researchers found that increasing RKIP expression in metastatic prostate cancer cells decreased their invasiveness and reduced lung metastases in mice. The study suggests that RKIP may be a suppressor of prostate cancer metastasis, offering new targets for cancer control.
Researchers discovered that a lost protein called PEDF can inhibit angiogenesis, a crucial process for tumor growth, in prostate cancer cells. Treatment with PEDF also triggered increased cell death in cancer cells, suggesting its potential as a new treatment option.
A new study suggests that PTEN dysfunction is responsible for 30-60% of melanomas and offers a potential therapeutic approach to kill cancer cells. The introduction of PTEN into melanoma cells could be a useful treatment option, but the cancer cells may eventually learn to evade this approach.
Researchers genetically inactivated an enzyme, acid sphingomyelinase, to show that damage to endothelial cells is another way radiation kills tumor cells. Tumors without the enzyme were radioresistant, while those with it responded well to low doses of radiation.
Researchers developed new methods for diagnosing breast cancer based on gene expression signatures, correlating with traditional pathological classifications. The study found that early-stage lesions contain molecular signatures reflecting tumor aggressiveness, potentially changing the course of cancer progression.